|

Emapalumab Clinical Trials

3 actively recruiting trials across 3 locations

▲ +1 trial since May 2026

Also known as: Anti-IFN gamma Monoclonal Antibody NI-0501, Anti-IFNg mAb NI-0501, Anti-interferon gamma Monoclonal Antibody NI-0501, Emapalumab-lzsg, Gamifant +4 more

Pipeline

Phase 1: 1Phase 2: 2

Top Sponsors

  • Memorial Sloan Kettering Cancer Center1
  • Marcela V. Maus, M.D.,Ph.D.1
  • City of Hope Medical Center1

Indications

  • Cancer3
  • Hypocellular Marrow1
  • Graft-versus-host-disease1
  • Cytopenia1
  • Large B-cell Lymphoma1

Duarte, California1 trial

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 1

Boston, Massachusetts1 trial

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Massachusetts General Hospital

Phase 2

New York, New York1 trial

A Study of Emapalumab for Pediatric Aplastic Anemia

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.